CMC and Pharmaceutical Quality

  • Quality Control & Quality Assurance (QC/QA) Systems
  • Pharmaceutical Product Development & Lifecycle Management
  • Process Validation & Continued Process Verification (CPV)
  • Pharmaceutical Quality System (PQS) & Quality Culture/Maturity
  • Quality by Design (QbD), control strategy, design space
  • ICH Q8–Q12 integration; lifecycle management & post-approval changes
  • Extractables/leachables, nitrosamines, and elemental impurities
  • Data integrity (ALCOA+), 21 CFR Part 11/Annex 11, CSV/CSA
  • Tech transfer playbooks: lab→pilot→commercial

Bringing a therapy from lab to market depends on rigorous control of the product and the process that makes it. CMC & Pharmaceutical Quality focuses on the science and systems that translate molecular promise into reliable, patient-ready medicines. The session spans control strategy design, specification setting, comparability, and lifecycle management so development teams can move confidently from clinical supply to commercial scale. Attendees will see how material attributes, process parameters, and analytical performance link together under risk-based frameworks to protect safety, efficacy, and continuity of supply. We examine stage-appropriate approaches—from Phase 1 flexibility to commercial robustness—showing how knowledge builds across unit operations, container–closure systems, and distribution environments. For professionals actively searching for a Pharmaceutical Science Conference, the program offers practical playbooks for integrating development reports, validation packages, and quality system records into reviewer-ready narratives. Core principles of Quality by Design are emphasized throughout, including design space, critical quality attributes, and continued process verification that aligns real production data with patient-focused specifications.

The discussion also addresses contemporary challenges: nitrosamine risk assessments, elemental impurities, extractables/leachables in single-use technologies, and data integrity across hybrid digital environments. Participants will learn how to apply ICH Q8–Q12 concepts to post-approval change management and how to use PACMPs to minimize regulatory friction while maintaining control. Case studies illustrate Module 3 pitfalls—unclear traceability, incomplete rationale for specs, or gaps in technology transfer—and demonstrate corrective actions that withstand inspections. Whether your product is a small molecule tablet, a complex biologic, or an advanced therapy, this session clarifies how to architect CMC dossiers that connect process understanding with consistent clinical performance.

Quality Systems and Lifecycle Mastery

Control Strategy Architecture

  • Translating CQAs and CPPs into sampling plans, limits, and decision rules.
  • Linking process knowledge to specification justification and lot release confidence.

Design Space & Verification

  • Defining ranges with mechanistic data and DoE outcomes.
  • Using CPV to confirm performance and drive continuous improvement.

Tech Transfer & Scale-Up

  • Capturing know-how for reliable lab→pilot→commercial transitions.
  • Managing equipment, materials, and site differences without losing control.

Impurities & Compatibility

  • Assessing nitrosamines, elemental impurities, and E&L with sound rationale.
  • Aligning container–closure integrity with product stability and sterility risks.

Digital & Data Integrity

  • ALCOA+ practices in hybrid systems and validated analytics.
  • Reviewer-friendly traceability from raw data to regulatory claims.

Post-Approval Change

  • Applying ICH Q12 and PACMP to streamline updates.
  • Maintaining global alignment across regions and licenses.

From Development to Durable Supply

Risk-Based Robustness
Builds justifiable specs and controls that protect patients.

Inspection Readiness
Turns knowledge into clear, auditable documentation and records.

Change Agility
Uses PACMP and Q12 to implement improvements without disruption.

Supply Resilience
Aligns sourcing, analytics, and manufacturing to prevent shortages.

Evidence Coherence
Connects Module 3 narratives with real process capability.

Cost and Efficiency
Reduces rework through right-first-time validation strategies.

Digital Confidence
Ensures data integrity and reviewability across systems.

Patient-Centered Quality
Keeps clinical performance at the core of every CMC decision.

Related Sessions You May Like

Join the Global Pharmaceutical Sciences Community

Connect with top researchers, industry experts, and innovators worldwide. Share your work and explore the latest advancements in drug discovery, translational research, and next-generation therapeutics.

Copyright 2024 Mathews International LLC All Rights Reserved

Watsapp
Top